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Summary
Background:	 NHS	 England	 has	 recommended	 a	multidisciplinary	 weight	manage‐
ment	services	 (MWMS—Tier	3	services)	 for	patients	requiring	specialized	manage‐
ment	of	obesity,	including	bariatric	surgery,	but	clinical	and	measurable	health‐related	
outcomes from these services remains fragmented. We therefore undertook a sys‐
tematic review to explore the evidence base of effect on body weight loss and co‐
morbidities	outcomes	of	Tier	3	or	UK	pre‐bariatric	MWMPs.
Methods:	AMED,	CINAHL,	EMBASE,	HMIC,	MEDLINE,	PsycINFO,	PubMed,	HDAS	
search	and	Google	Scholar	were	searched	from	January	2000	to	September	2017	in	
a free‐text fashion and crossed‐references of included studies to identify potential 
illegibility.	 Inclusion	criteria	were	as	follows:	 (a)	published	Tier	3	original	study	ab‐
stracts/articles;	 (b)	 intervention	studies	with	before	and	after	data;	 (c)	studies	that	
included	any	sort	of	MWMPs	conducted	on	British	residents	with	obesity;	and	(d)	
studies included T2DM measurements in a MWMPs.
Results:	 In	total,	19	studies	met	the	 inclusion	criteria.	The	total	number	of	partici‐
pants	analysed	was	N	=	11,735.	Baseline	accumulative	average	BMI	was	calculated	at	
42.54 kg/m2,	weight	117.88	kg	and	waist	circumference	126.9	cm.	And	at	6	months,	
40.73	kg/m2,	 112.17	kg	 and	 120.3	cm,	 respectively.	 Secondary	 outcome	 variables	
were	as	improved	with	reduction	in	HbA1c,	fasting	blood	sugars,	insulin	usage	and	
blood	pressure.	Physical	activity	increased	at	3	months	then	declined	after	6	months	
with no significant changes in cholesterol levels.
Conclusion:	Tier	3	and	MWMPs	have	a	short	to	mid‐ranged	positive	effect	on	obese	
patients	(BMI	≥30	kg/m2)	living	in	the	UK	regarding	accumulated	reduction	in	weight,	
glycaemic	control,	blood	pressure	and	with	subtle	improvements	in	physical	activity.
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1  | BACKGROUND
Morbid obesity is an increasing lifelong chronic condition that no 
country has yet succeeded to tackle.1	In	England,	the	prevalence	of	
obesity	 is	 among	 the	 highest	 in	 Europe.2 Two‐thirds of adults are 
overweight	 and	 one	 in	 four	 are	 obese	 (Body	Mass	 Index	 (BMI)	 of	
>30	kg/m2).3,4	McKinsey	Global	 Institute	 reported	 that,	 second	 to	
smoking,	obesity	has	the	largest	impact	on	the	public	health	budget	
with	an	estimated	annual	cost	to	the	United	Kingdom’s	(UK)	National	
Health	Service	(NHS)	of	£44.7b.5 The importance of a range of obe‐
sity prevention initiatives comes from the increasing number of 
health	complications	and	their	related	high	cost.	High	Blood	Pressure	
(BP),	type	2	diabetes	mellitus	(T2DM),	heart	attacks,	strokes,	cancers	
and	other	health	issues,	for	instance,	are	evidently	associated	to	the	
conditions of being overweight or obese.4
Even	though	bariatric	surgical	intervention	is	a	proven	effective	
approach	for	treating	chronic	obesity,	access	and	eligibility	for	bar‐
iatric surgery remains low.6	The	reasons	for	this	are	multifactorial,	
but may include a lack of developed infrastructure for medical as‐
sessment	 and	 services,	 unclear	 referral	 procedures,	 as	well	 as	un‐
certainties regarding costs and long‐term outcomes.7	 In	 England,	
the	 rate	of	bariatric	 surgical	 operations	dropped	by	31%	between	
2011‐2012	and	2014‐2015	(from	8794	to	6032	operations,	respec‐
tively).4	It	is	much	worse	in	Scotland	and	Wales,	and	there	is	no	NHS	
bariatric surgery performed in Northern Ireland.8 Provision of bar‐
iatric	intervention	by	NHS	is,	therefore,	less	than	1%	of	the	national	
need.8
In	the	UK,	obesity	is	managed	through	a	4‐levels	tiered	pathway.	
Tier 1 and 2 are focused on universally environmental and popu‐
lation‐wide prevention services.4,9	 Following	 this,	 individuals	 with	
more complex obesity and/or medical needs are considered for Tier 
3	Multidisciplinary	Weight	Management	Service	 (MWMS),10 which 
may lead to a Tier 4 service for consideration of bariatric surgery.4,11 
Tier	3	MWMS	consists	of	a	 (bariatric)	physician,	a	dietitian,	a	spe‐
cialist nurse and a clinical psychologist with access to physical ther‐
apy.4	 All	 adults	 identified	with	 a	BMI	 of	 ≥40	kg/m2,	 or	 ≥35	kg/m2 
with comorbidities are eligible for bariatric surgery following assess‐
ment	and	input	from	Tier	3	services.	Tier	3,	in	this	context,	could	also	
apply	to	a	“Weight	Assessment	and	Management	Clinic”	provided	by	
primary or secondary care.4
Within	a	Tier	3	service,	strategies	are	implemented	to	make	crit‐
ical changes about eating and physical activity habits to improve 
health and identify risk factors so that the planned intervention ad‐
dresses and improves all elements comprehensively.4	Screening	for	
hormonal or genetic causes of excessive weight as well as all related 
comorbidities and disabilities are conducted by the bariatric physi‐
cian and each individual should have their own tailored lifestyle and 
healthful	eating	advice	provided	by	a	specialist	dietitian.	In	addition,	
patients are screened for signs of psychiatric comorbidities due to 
the	well‐recognized	 link	between	obesity	with	many	psychological	
disorders	 such	 as	 anxiety,	 depression,	 self‐harm	 and	 suicidal	 be‐
haviours,	eating	disorders	(such	as	binge	eating	and	bulimia	nervosa),	
borderline	 personality	 disorders,	 alcohol	 and	 substance	 misuse,	
childhood	adversity,	among	others.	Patients	with	proven	effort,	an	
adequate	 timeframe	prescribed	by	 the	multidisciplinary	 team,	 and	
with	 right	weight	criteria	and	medically	optimized	 for	 surgery,	will	
then be advised to progress towards the Tier 4 bariatric surgical 
intervention.4,12
Although	our	understanding	of	the	benefits	of	a	Tier	3	service	
is	 growing—based	 on	 our	 appraisal	 of	 current	 literature,11,4,13 cur‐
rent	evidence	remains	fragmented	and	needs	to	be	synthesized	to	
produce a more comprehensive picture which will help to translate 
to a safe and cost‐effective approach to the management of morbid 
obesity	in	the	UK.	We,	therefore	plan	to	explore	the	evidence	base	
of effect magnitude on body weight loss in addition to other health‐
related	outcomes	of	 severely	obese	adults	undergoing	 a	Tier	3	or	
pre‐bariatric Multicomponent Weight Management Programmes 
(MWMPs)	in	the	UK.	We	include	obese	adults	in	the	UK	with	a	BMI	
≥30	kg/m2	who	have	been	enrolled	in	a	Tier	3	service	or	in	any	form	
of MWMP for losing weight.
2  | METHODS
2.1 | Literature search
A	 free‐text	 literature	 search	 of	 articles	 published	 from	 January	
2000	 through	 September	 2017	 was	 performed.	 The	 search	 used	
the	Healthcare	Databases	Advances	Search	(HDAS)	via	the	National	
Institute	 for	 Health	 and	 Care	 Excellence’s	 (NICE)	 evidence	 ser‐
vices with access to the following electronic bibliographical data‐
bases:	AMED,	CINAHL,	EMBASE,	HMIC,	MEDLINE,	PsycINFO	and	
PubMed.	An	extended	search	was	conducted	using	Google	Scholar	
after	 reviewing	additional	 studies	 that	were	 included	by	Brown	et	
al	(2017)	systematic	review.12	Terms	used	were	related	to	“obesity”	
and	 “overweight”	 in	 conjunction	 with	 geographical	 restrictions	 to	
the	UK	(eg,	England,	Wales,	Scotland,	North	Ireland).	Terms	related	
to	MWMS,	 Specialist	Weight	Management	 (SWM)	 and	 Tier	 3	 (eg,	
weight	management	services,	weight	reduction	programmes,	weight	
management	 interventions,	multidisciplinary	weight	 loss	 initiatives	
and	multicomponent	weight	loss	schemes)	were	utilized	on	the	titles	
and	abstracts	search.	In	addition,	we	screened	reference	sections	of	
all included studies to identify potential illegible articles that meet 
the	inclusion	criteria	of	this	review.	See	Figure	1	flow	chart.
2.2 | Study selection
In	this	review,	we	use	a	similar	pragmatic	selection	approach	to	Brown	
et	al	 (2017).12	Tier	3	studies	 for	adults	 (18	years	and	over	with	no	
upper	age	limit)	with	a	mean	baseline	BMI	of	≥40	or	≥35	kg/m2 with 
a	 comorbidity	 or	 ≥30	kg/m2	with	 T2DM	are	 included.	 In	 addition,	
all	UK	multicomponent	pre‐bariatric	weight	 loss	 interventions	that	
were	planned	and	delivered	 for	obese	adults	with	BMI	≥30	kg/m2 
published	since	January	2000	until	September	2017	were	screened	
for	potential	inclusion.	Inclusion	criteria	follow:	(a)	published	Tier	3	
original	study	abstracts	and	articles;	(b)	intervention	studies	with	be‐
fore	and	after	data;	(c)	studies	including	any	sort	of	MWMP	planned	
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for	morbidly	obese	British	 residents;	 and	 (d)	 studies	 that	 included	
T2DM measurements in a MWMP for overweight adults. We ex‐
cluded studies on children or adolescents and all studies conducted 
within	non‐British	weight	reduction	intervention	programmes.	The	
decision to include or exclude studies was initially made based on 
the	article	title,	then	abstract	and	finally	review	the	full‐text	article.
2.3 | Data extraction
We evaluated each of the included studies and extracted four data 
aspects:	(a)	descriptive	to	study	design	and	intervention	(Table	S1);	
(b)	 sample	 size	 and	 demographic	 characteristics	 (Table	 S2);	 (c)	 as‐
sessed	measurements	(Table	S3);	and	(d)	health	outcome	records	at	
baseline	followed	by	points	of	time	intervals	(Tables	S4‐S9).	For	each	
segment,	authors	 (year	and	country	where	 intervention	was	deliv‐
ered)	are	indicated.
In	the	descriptive	of	study	design	and	intervention,	we	included	
the	following:	sitting,	study	design,	aim,	type	of	intervention,	a	brief	
description	of	intervention,	inclusion	and	exclusion	criteria,	duration	
and lost‐to‐follow‐up or drop‐out data rate. In the demographics: 
sample	size	(N),	age	(years),	gender	(female,	%),	ethnicity,	socioeco‐
nomic	status	(SES),	education	level,	marital	status	and	type	of	finan‐
cial	support.	On	the	assessed	measurements	(n,	%):	mental	disorder,	
anxiety,	depression,	sleep	apnoea,	hypertension,	cardiovascular	dis‐
ease	(CVD),	ischaemic	heart	disease,	hyperlipidaemia,	diabetes	mel‐
litus	(DM),	impaired	fasting	glucose,	insulin	use,	oral	hypoglycaemic	
and incretin based.
For	 the	 baseline,	 3,	 6,12,	 18	 and	 24	months,	we	 extracted	 (or	
calculated)	 the	 following	variables	of	health	outcome	 results:	BMI	
(kg/m2),	weight	 (kg),	waist	 circumference	 (cm),	5%	or	more	weight	
loss	 achieved	 (per	 cent),	 10%	weight	 loss	 achieved	 (per	 cent),	 lost	
≥5	kg	(per	cent),	lost	≥10	kg	(per	cent),	lost	0	to	≤5	kg	(per	cent),	lost	
5	to	≤10	kg	(per	cent),	lost	10	to	≤15	kg	(per	cent),	lost	15	to	≤20	kg	
(per	cent),	lost	≥20	kg	(per	cent),	mean	weight	loss	(kg	and	Standard	
Deviation	 [SD]),	 percentage	 of	 body	 weight	 lost,	 BP	 (systolic	 and	
diastolic),	 hypertension,	 insulin	 usage,	 Fasting	 Blood	 Sugar	 (FBS)	
(mmol/L),	glucose	(mmol/L),	HbA1ca	(%	and	mmol/mol‐1),	cholesterol	
(mmol	L‐1),	HDL	and	LDL	(mmol	L‐1),	total	cholesterol,	triacylglycerol	
and levels of physical activity.
We were not able to extract food intake records because of het‐
erogeneity of stratification methods used by a number of studies in 
addition	to	concerns	of	related	recall	bias.	We	support	Brown	et	al’s	
(2017)	decision	regarding	the	difficulty	in	producing	a	meta‐analysis	in	
reviewing	Tier	3	and	all	MWMPs	due	to	heterogeneity.12 The increased 
rate of patient drop‐out and apparent risk of bias are also preventive 
factors	to	a	meta‐analysis.	Thus,	narrative	synthesis	is	carried	out.
F I G U R E  1  Preferred	reporting	items	for	systematic	reviews	and	meta‐analyses	(PRISMA)	flow	chart37
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TA B L E  1  List	of	included	studies	with	summary	characteristics	and	results
Author (year) 
Country Sample size (N) Intervention Study design
Duration 
(months)
Age (yrs) 
Female (%)
Initial BMI & Weight 
(kg)
Endpoint BMI & Weight 
(kg) Initial outcome variables
Endpoint outcome 
variables
Barratt	(2008)17 
England
38 Dietetic	led	(Lifestyle) Retrospective case‐control analysis 6 42.9	±	9.9 
100.0
40.49	±	8.36a 
109.53	±	23.92a
37.46a 
Weight NR
BPb: 124/80 
HbA1c:	47.2 
Cholesterol: 4.80 
HDL:	1.30	±	0.45 
LDL:	2.87	±	0.77 
Triacylglycerol: 
1.49	±	0.79
119/79 
40.2* 
4.79 
1.37	±	0.32 
2.81	±	0.78 
1.43	±	0.97
Brown	(2015)20 
England
828 SWM	(SLiM) Single‐group	observational	cohort	 
(service	evaluation)
6 48.2	±	11.6 
73.7
49.1	±	9.2 
135	±	28.1
47.6a 
131.4a
HbA1c:	63.9a 59.6a,*
Cheyette	(2007)16 
England
49 SWM	(Weight	No	More) RCT 4 56.7	±	9.7 
47.0
34.1	±	4.7 
97.2	±	15.1
BMI	NR 
93.4	±	14.2
HbA1c:	68.3a 
Insulin	usage:	72.0a
65.0a 
62.0	±	30.4
Hughes	(2015)25 
UK 
ABSTRACT
272 Tier	3 Prospective cohort 12 NR 44.0 
123.9
BMI	NR 
115.6
NR NR
Jackson	(2007)26 
England
89 Specialist	health	visitor	with	expertise	in	weight	
management
A	prospective	before	and	after	study	based	 
in one primary healthcare centre
12 55.8	±	13.8 
80.9
37.4	±	5.85 
103.16	±	16.9
33.11	±	5.7* 
91.64	±	19.0*
BP:	138.4/78.4 
FBS:	5.44	±	1.08 
Cholesterol:	5.38	±	1.19
124.4/69.6* 
5.04	±	0.60* 
5.38	±	1.33
Jennings	(2014)21 
England
230 Tier	3	SWMS Single‐group	observational	cohort	 
(service	evaluation)
24 52.7	±	13.6 
70.0
44.1	±	7.8 
124.4	±	27.3
41.0	±	7.6* 
115.8	±	26.0
BP:	131/76 
Waist:	128	±	16.2 
HbA1c:	57.8	±	15.3 
PA	Score:	3.4	±	1.0
122/71* 
118	±	15.4* 
53.7	±	14.1* 
2.8	±	1.2*
Kininmonth	(2016)22 
Huddersfield,	UK 
ABSTRACT
280 Tier	3	SWMS Retrospective cohort 6 Age	NR 
67
49.4	±	7.4 
138.9	±	27.2
48.5	±	7.5 
136.3	±	27.5
NR NR
Lean	(2013)18 
Scotland
91 Low‐energy	Liquid	diet	LELD	and	Food	
Reintroduction
Feasibility study 12 45.7	±	10.7 
81.3
48.0	±	7.6 
131.1	±	25.2
BMI	NR 
118.7a
NR NR
Logue	(2014)27 
Scotland
1838 Structured	educational	lifestyle	and	GCWMS Prospective observational study 12 49.1	±	13.5 
72.9
43.3 
118.1
NR NR NR
MacLaughlin	(2015)23 
England
338 Renal Weight Management Programme Retrospective cohort study 12 52.3	±	12.8 
45.0
36.6	±	5.3 
Weight NR
BMI	NR 
‐	4.3	reduction*
NR NR
McLean	(2016)24 
Scotland
1838 GCWMS	for	anxiety	and	depression Retrospective cohort study 12 48.1	±	12.5a 
72.2a
43.77	±	7.23a 
122.5	±	24.2a
NR NR NR
Melville	(2011)28 
Scotland
54 (TAKE	5)	GCWMS Before	and	after	study	(without	control) 6 48.3	±	12.0 
59.3
40.0	±	8.0 
100.6	±	26.8
39.1	±	8.2* 
96.1	±	26.9*
Waist:	122.1	±	15.7 115.8	±	16.7*
Morrison	(2012)29 
Scotland
2976 SWM	GCWMS Prospective uncontrolled cohort study 24 46.0 
72.4
BMI	stratifiedc 
Weight NR
Stratified NR NR
Nield	(2016)30 
England
288 Specialist	Community	Weight	Management	
Programme
Prospective cohort observational study 6 Age‐stratified 
66.0
45.5	±	6.6 
126.9	±	21.5
43.32a,* 
120.6a,*
PA	min/week:	113.2	±	233.2 
Waist:	130.7	±	14.6
107.4	±	209.7* 
125.0a,*
Ross	(2008)31 
England
1906 Counterweight	Programme	SWM Prospective uncontrolled cohort study 24 49.4	±	13.5 
77.0
37.1	±	6.0 
101.1
36.02a 
98.04a
Stratified Stratified
Rowe	(2005)32 
England
100 Orlistat and behavioural interventions for diet 
and exercise
Prospective observational without control 24 54.6	±	11.2a 
55.0
39.5	±	6.5 
112.0	±	20.9a
BMI	NR 
99.7	±	32.4*
HbA1c:	59.6a 
Insulin	usage:	130	±	135.4
52.8a,* 
90	±	124.1*
Ryan	(2017)33 
England
141 SWMS	multidisciplinary,	biopsychosocial	
approach
Before	and	after	study	(without	control) 12 52.2	±	11.9 
70.0
46.3	±	7.2 
127.2	±	23.0
BMI	NR 
Weight stratified
Pain: stratified Stratified
Turner	(2015)15 
Wales,	UK
180 MDWMC	‐	Tier	3 Service	evaluation	by	semi‐structured	interviews	and	questionnaires 24 Age	NR 
72.7a
NR NR NR NR
Wright	(2012)19 
Scotland
199 SWMP Cross‐sectional 6 49.7	±	12.6 
76.4a
BMI	NR 
114.5	±	23.4
BMI	NR 
109.4	±	23.1*
NR NR
NR,	Not	Reported.
aObserved,	calculated	or	converted	by	reviewer.	
bUnits:	BMI	(kg/m2);	Weight	(kg);	Blood	Pressure	(BP)	(mmHg);	HbA1c	(mmol/mol);	Fasting	Blood	Sugars	(mmol/L);	Insulin	usage	(Units);	
Cholesterol	(mmol/L);	HDL&	LDL	(mmol/L);	Triacylglycerol	(mmol/L);	Waist	circumference	(Centimetres);	Physical	Activity	(PA)	in	a)	score:	
where	4	being	inactive	&	1	active;	and	in	b)	minutes	per	week.	
cFor	more	details	on	stratified	data	see	Appendix	Supporting	information	Tables	S4‐S9.	
*With	statistical	significance	(ie,	P	<	0.05).	
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1.49	±	0.79
119/79 
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131.4a
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in one primary healthcare centre
12 55.8	±	13.8 
80.9
37.4	±	5.85 
103.16	±	16.9
33.11	±	5.7* 
91.64	±	19.0*
BP:	138.4/78.4 
FBS:	5.44	±	1.08 
Cholesterol:	5.38	±	1.19
124.4/69.6* 
5.04	±	0.60* 
5.38	±	1.33
Jennings	(2014)21 
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24 52.7	±	13.6 
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44.1	±	7.8 
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49.4	±	7.4 
138.9	±	27.2
48.5	±	7.5 
136.3	±	27.5
NR NR
Lean	(2013)18 
Scotland
91 Low‐energy	Liquid	diet	LELD	and	Food	
Reintroduction
Feasibility study 12 45.7	±	10.7 
81.3
48.0	±	7.6 
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1838 Structured	educational	lifestyle	and	GCWMS Prospective observational study 12 49.1	±	13.5 
72.9
43.3 
118.1
NR NR NR
MacLaughlin	(2015)23 
England
338 Renal Weight Management Programme Retrospective cohort study 12 52.3	±	12.8 
45.0
36.6	±	5.3 
Weight NR
BMI	NR 
‐	4.3	reduction*
NR NR
McLean	(2016)24 
Scotland
1838 GCWMS	for	anxiety	and	depression Retrospective cohort study 12 48.1	±	12.5a 
72.2a
43.77	±	7.23a 
122.5	±	24.2a
NR NR NR
Melville	(2011)28 
Scotland
54 (TAKE	5)	GCWMS Before	and	after	study	(without	control) 6 48.3	±	12.0 
59.3
40.0	±	8.0 
100.6	±	26.8
39.1	±	8.2* 
96.1	±	26.9*
Waist:	122.1	±	15.7 115.8	±	16.7*
Morrison	(2012)29 
Scotland
2976 SWM	GCWMS Prospective uncontrolled cohort study 24 46.0 
72.4
BMI	stratifiedc 
Weight NR
Stratified NR NR
Nield	(2016)30 
England
288 Specialist	Community	Weight	Management	
Programme
Prospective cohort observational study 6 Age‐stratified 
66.0
45.5	±	6.6 
126.9	±	21.5
43.32a,* 
120.6a,*
PA	min/week:	113.2	±	233.2 
Waist:	130.7	±	14.6
107.4	±	209.7* 
125.0a,*
Ross	(2008)31 
England
1906 Counterweight	Programme	SWM Prospective uncontrolled cohort study 24 49.4	±	13.5 
77.0
37.1	±	6.0 
101.1
36.02a 
98.04a
Stratified Stratified
Rowe	(2005)32 
England
100 Orlistat and behavioural interventions for diet 
and exercise
Prospective observational without control 24 54.6	±	11.2a 
55.0
39.5	±	6.5 
112.0	±	20.9a
BMI	NR 
99.7	±	32.4*
HbA1c:	59.6a 
Insulin	usage:	130	±	135.4
52.8a,* 
90	±	124.1*
Ryan	(2017)33 
England
141 SWMS	multidisciplinary,	biopsychosocial	
approach
Before	and	after	study	(without	control) 12 52.2	±	11.9 
70.0
46.3	±	7.2 
127.2	±	23.0
BMI	NR 
Weight stratified
Pain: stratified Stratified
Turner	(2015)15 
Wales,	UK
180 MDWMC	‐	Tier	3 Service	evaluation	by	semi‐structured	interviews	and	questionnaires 24 Age	NR 
72.7a
NR NR NR NR
Wright	(2012)19 
Scotland
199 SWMP Cross‐sectional 6 49.7	±	12.6 
76.4a
BMI	NR 
114.5	±	23.4
BMI	NR 
109.4	±	23.1*
NR NR
NR,	Not	Reported.
aObserved,	calculated	or	converted	by	reviewer.	
bUnits:	BMI	(kg/m2);	Weight	(kg);	Blood	Pressure	(BP)	(mmHg);	HbA1c	(mmol/mol);	Fasting	Blood	Sugars	(mmol/L);	Insulin	usage	(Units);	
Cholesterol	(mmol/L);	HDL&	LDL	(mmol/L);	Triacylglycerol	(mmol/L);	Waist	circumference	(Centimetres);	Physical	Activity	(PA)	in	a)	score:	
where	4	being	inactive	&	1	active;	and	in	b)	minutes	per	week.	
cFor	more	details	on	stratified	data	see	Appendix	Supporting	information	Tables	S4‐S9.	
*With	statistical	significance	(ie,	P	<	0.05).	
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2.4 | Risk of bias assessment
Two	authors	(MA	and	UA)	have	independently	assessed	all	included	
studies	 using	 the	 Cochrane	 Handbook	 for	 Systematic	 Reviews	 of	
Intervention tool.14 They evaluated the possibility of the following 
bias	 elements:	 allocation	 sequence,	 allocation	 concealment,	 blind‐
ing	 (of	participants,	personnel	and	outcome	assessors),	 incomplete	
outcome data and selective outcome for reporting or publication of 
data.
3  | RESULTS
1,342	 article	 abstracts	 were	 identified	 as	 potentially	 relevant,	 and	
after	 reviewing	 418	 in	 full‐text,	 11	 articles	 and	 2	 published	 study	
abstracts met the inclusion criteria and were included in the review. 
Grey	 literature	search	and	 reference	 lists	check	 including	Brown	et	
al’s	(2017)	systematic	review	yielded	additional	6	study	articles	(see	
Figure	1	Flow	chart).	In	total,	19	studies	are	eligible	for	inclusion.	The	
reasons	for	excluding	405	articles	were	as	follows:	a)	not	being	a	UK	
intervention;	b)	not	Tier	3	or	MWMP;	c)	did	not	meet	BMI	criteria;	d)	
intervention	intended	for	children	or	adolescents;	e)	no	usable	data	
(eg,	qualitative	approach	for	satisfactory	records);	and	f)	post‐bariatric	
groups	comparison.	The	19	included	studies	were	all	published	within	
the	last	17	years	in	15	different	journals,	all	conducted	in	the	UK.
Table 1 present study design as well as an intervention type and 
descriptive	summary	of	all	included	studies,	demographic	character‐
istics	of	participants	(N	=	11,735),	reported	measurements	and	base‐
line characteristics and average reported health outcome results in 
three,	six,	twelve,	eighteen,	twenty‐four‐month	intervals.	The	clear	
majority	of	studies	(90%)	did	not	reach	18	and	24	months,	thus	re‐
porting	MWMS	 true	 effect	 at	 these	particular	 points	 of	 time	was	
difficult.	However,	a	decision	was	made	to	evaluate	findings	at	the	
last endpoint possible as this may add value.
The	majority	of	included	studies	(95%)	reported	our	primary	out‐
come	of	interest	in	weight	and/or	BMI	from	the	baseline	records	up	
to	their	study	endpoint.	Turner	et	al	(2015)	was	the	study	article	that	
did	not	 report	weight	 in	any	 form	at	baseline;	however,	 this	study	
reported	rates	of	participants	who	achieved	≥5%	and	≥10%	weight	
reduction	at	their	intervention	endpoint	of	12	months	(ie,	36%	and	
37%,	respectively).15
3.1 | Study design
The	study	design	ranged:	one	randomized	controlled	trial	(RCT),16 a 
semi‐structured	interview	(service	quality	evaluation)	study,15 a ret‐
rospective	 case‐control,17	 a	 feasibility	 study,18	 a	 cross‐sectional,19 
two	 single‐group	 observational	 cohort	 (service	 evaluation)	 stud‐
ies,20,21	 three	 retrospective	 (data	 analysis)	 cohort	 studies22‐24 and 
nine prospective cohort studies.25‐33
Five	studies	investigated	the	effect	of	Tier	3	services.15,19,21,22,25 
Three	 looked	 into	 the	 Glasgow	 and	 Clyde	 Weight	 Management	
Service	 (GCWMS).24,27,29 Whereas the rest focused on further 
MWMPs	 including:	 “TAKE‐5”	 GCWMS,28	 Dietetic	 led,17	 “SLiM”	
SWM,20	 “Weight	 No	 More”	 SWM,16 specialist health visitor pro‐
gramme,26	 Low‐Energy	 Liquid	 Diet	 (LELD)	 food	 reintroduction,18 
Renal	Weight	Management	Programme	 (RWMP),23 specialist com‐
munity	 weight	 reduction	 programme,30	 “CounterWeight”	 SWM,31 
Orlistat weight reduction 32 and biopsychological multidisciplinary 
programme.33 Further details on study design and intervention de‐
scription	are	in	Table	1	and	Table	S1.
3.2 | Risk of bias
All	studies	showed	high	risk	in	selection,	performance,	detection	and	
attrition	bias.	This	is	because	all	included	studies,	except	for	the	only	
RCT,16	were	designed	as	evaluation	(before	and	after),	retrospective	
analysis or uncontrolled prospective investigation. The risk of publi‐
cation or reporting bias was low to unclear for all studies which may 
add	to	the	overall	reliability	(Figure	2).	Attrition	bias	was	evaluated	
high	in	consequence	of	the	increased	pattern	of	patients’	drop‐out	
rate; which was not fully investigated or discussed.
3.3 | Participants’ characteristics
Women comprised the largest percentage of participants in all 
except	 two	 studies:	 Cheyette	 (2007):	 47%;	 and	 MacLaughlin	 et	
al	 (2015):	 45%.16,23	One	 study	 did	 not	 include	men	 (Barratt	 et	 al,	
2008).17	Age	ranged	from	18	to	75	years;	mean	age	ranged	between	
40	and	60	years	(mean:	49.2	years).	Ethnicity	was	reported	in	groups	
by	 5	 (26%)	 studies	with	 a	 clear	majority	 being	Caucasian	 (ranging	
from	47%	to	96%);	and	with	Black	African	or	Asian	descendants	re‐
ported second.17,20,23,28,30
F I G U R E  2   Risk of bias assessment 
authors' judgements about each risk of 
bias item for each included study
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3.4 | Socioeconomic status
SES	was	reported	in	7	(37%)	studies	in	a	five‐level	scoring	classifica‐
tion.19,24,27,29‐31,33	 In	 studies	 that	 included	 SES,	 the	most	 deprived	
was reported with the highest rate compared to all other deprivation 
levels	(ranging	from	27%	to	62%).	Only	Jennings	et	al’s	(2014)	study	
reported	 education	 level,	 which	 included	 three	 layers	 (≤15	years:	
30%,	15‐19	years:	52%,	and	≥19	years:	18%).21	In	addition,	Melville	
et	 al’s	 (2011)	 study	 reported	 participants’	marital	 status	 (Married:	
2%;	Single:	98%)	and	their	type	of	financial	support	(Live	indepen‐
dently:	7.4%;	Family	carer:	31.5%;	Paid	carer:	61.1%).28
3.5 | Primary outcome results
Baseline	BMI	was	 reported	by	90%	of	 included	studies	except	 for	
Turner	et	al	(2015)	and	Wright	et	al	(2012)	and	ranged	from	30.1	to	
49.1	kg/m2.16‐18,20‐33	Two	studies	reported	BMI	in	stratified	group‐
ings	which	 left	 the	 accumulative	 average	 BMI	 calculated	 from	 16	
studies at 42.54 kg/m2.	 Baseline	weight	 in	 kilograms	was	 also	 re‐
ported	by	90%	of	included	studies	except	for	Morrison	et	al	(2011)	
and	Turner	et	al	(2015).16‐28,30‐33 Turner et al reported participants 
that	 lost	 weight	 at	 12	months,	 which	 was	 their	 intervention	 end‐
point.15	Wright	et	al	 (2012)	 reported	weight	at	baseline	and	at	 six	
months	 (114.5	±	23.4	kg	 and	 109.4	±	23.1	kg,	 P	<	0.001,	 respec‐
tively).19 The baseline accumulative average of weight is calculated 
at	117.88	kg.	See	Table	2.
At	three	months,	the	calculated	average	BMI	from	six	studies	is	
42.40 kg/m2; 20‐22,26,30,31 five of which reported statistical signifi‐
cance at (P	<	0.001).20,21,26,30,31	Morrison	et	al	(2011),	however,	re‐
ported	BMI	in	stratification.29 The mean reduction in weight ranged 
from	3.34	±	3.53	to	4.11	±	4.95	kg	(P	<	0.001)	in	6	studies.20‐22,26,30,31 
An	average	of	weight	 reduction	with	no	BMI	 informed	and	with	a	
reported	 statistical	 significance	 by	 Cheyette	 (2007)	 (2.2	kg	 ±2.7;	
P	<	0.01).16	 In	 total,	 eight	 studies	 (42%)	 reported	 a	 change	 in	BMI	
and/or	weight	at	three	months	from	their	baseline,	and	the	major‐
ity reported statistically significance weight reduction with an ac‐
cumulative average of 114.48 kg.16,20‐22,26,29‐31	 Six	 studies	 (31%)	
reported	a	percentage	of	participants	who	lost	5%	or	more	of	their	
initial	weight	(calculated	mean:	22.95%	of	participants).21,22,24,27,30,31 
Jennings	et	al	 (2014)	was	 the	only	study	 to	 report	a	10%	or	more	
weight	reduction	rate	among	participants	(3.6%).21 Details on rates 
are	summarized	in	Table	3.
At	 six	 months,	 11	 studies	 (58%)	 reported	 changes	 in	 BMI	 or	
weight	(kg)	or	both.16,17,19‐22,26,28,30‐32 The calculated average reduc‐
tion	in	BMI	is	1.89	kg/m2	ranging	from	0.8	to	3.3	kg/m2 in eight stud‐
ies	with	 a	 cumulative	 average	 of	 40.73	kg/m2.17,20‐22,26,28,30,31 The 
mean	 reduction	 in	weight	 (kg)	was	 reported	by	 ten	 studies	 (53%),	
with	a	calculated	accumulative	average	of	112.17	kg.16,19‐22,26,28,30‐32 
Nine	studies	 (47%)	reported	a	5%	or	more	weight	 loss	rate	among	
participants	 with	 a	 calculated	 average	 of	 39.2%.19‐21,24,27,28,30‐32 
Only	two	studies	(11%)	reported	an	average	of	10.0%	of	participants	
whom	lost	10%	or	more	from	their	initial	weight.20,21
Baseline 3 mo 6 mo 12 mo 18 mo 24 mo
BMI	(kg/m2) 42.54(16)a 42.40(6) 40.73(8) 36.67(3)
Weight	(kg) 117.88(16) 114.48(7) 112.17(10) 102.89(5) 112.0(1) 105.95(2)
Waist circmf. 
(cm)
126.9(3) 125.3(2) 120.3(3) 118.0(1)
HbA1c	
(mmol/mol)
58.8(5) 56.5(2) 53.8(5) 59.4(2)
FBS	(mmol/L) 5.44(1) 5.08(1) 5.14(1) 5.04(1)
Insulin usage 
(Units)
101.0(2) 58.7(1) 76.55(2) 62.0(1)
Cholesterol 
(mmol/L)
5.09(2) 5.18(1) 5.01(2) 5.38(1)
BP	(mmHg)
Systolic 134.7(2) 129.5(1) 124.5(2) 123.2(2)
Diastolic 77.2 72.6 75.9 70.5
PA
Out of 4b 3.4 2.9 2.7 2.8
Min/weekc 113.2 123.2 107.4
Drop‐out 
(%)
9.1(1) 33.4(5) 44.1(8) 74.1(4)
aSuperscript	in‐bracket	numbers	represent	count	of	studies	contributed	in	calculating	the	correlated	
average. 
bInverse	score	used	by	Jennings	et	al	(2014)	to	report	physical	activity	where	4	being	inactive	and	1	
is active. 
cPhysical	activity	reported	by	Nield	et	al	(2016)	in	minutes	per	week.	
TA B L E  2  Summary	of	calculated	
average primary and secondary outcome 
results covered and reported by the 
included studies
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At	one	year,	five	studies	(26%)	reported	a	change	in	BMI	or	weight	
or both.16,21,25,26,31	 BMI	 reduction	 was	 reported	 by	 three	 studies	
(16%)	with	a	calculated	average	of	36.67	kg/m2.21,26,31 Weight reduc‐
tion	was	reported	by	five	studies	(26%),	ranging	from	2.8	to	11.6	kg	
reduction	and	with	a	calculated	average	of	102.89	kg.16,21,25,26,31	An	
average	of	43.4%	of	participants	have	achieved	5%	or	more	weight	
loss;	 as	 reported	 by	 seven	 studies	 (37%).15,21,24,25,27,31,33	 At	 this	
point,	only	two	studies	(11%)	have	reported	10%	or	more	weight	loss	
with	a	calculated	average	29.4%	of	participants.15,21
At	eighteen	months,	Jennings	et	al	(2014)	was	the	only	study	that	
reported change in kilograms.21 The mean reduction in weight was 
12.4 kg (P	<	0.001)	 with	 47.9%	 of	 the	 remaining	 participants	 who	
lost	5%	or	more	and	26%	 lost	10%	or	more	of	 their	 initial	weight.	
At	eighteen	months,	there	were	no	additional	outcome	variables	re‐
ported by any of the included studies.
At	 two	 years,	 three	 studies	 (16%)	 briefly	 reported	 weight	
change.21,29,32	Jennings	et	al	(2014)	and	Rowe	et	al	(2005)	reported	
weight change in kilograms from the remaining participants with an 
average	reduction	by	11.9	kg	(P	<	0.01)	with	a	cumulated	average	of	
105.95	kg.21,32	Morrison	et	al	(2011)	reported	only	the	rate	of	par‐
ticipants	that	lost	5	kg	or	more	(13.6%).29	At	this	point,	there	were	
no additional outcome variables reported by any of the included 
studies.	In	addition,	no	prospective	study	went	beyond	two	years	of	
follow‐up.	Tables	2	and	3	represent	calculated	average	results.
3.6 | Secondary outcome variables
The included studies reported secondary outcome variables in a 
heterogeneity that made tracking a set of health outcome variables 
problematic.	 Eight	 studies	 (42%)	 reported	 secondary	 health	 out‐
come	variables	at	baseline:	waist	circumference,	glycaemic	control,	
lipids,	BP	and	physical	activity.16,17,20,21,26,28,30,32 Details on baseline 
results are in Table 2.
At	three	months,	Jennings	et	al	(2014)	and	Nield	et	al	(2016)	re‐
ported significant reduction in waist circumference by an average 
of 4.02 cm (P	<	0.001).	The	accumulative	average	of	waist	 circum‐
ference	 was	 125.3	cm.	 They	 also	 reported	 significant	 increase	 in	
physical	activity	levels,	but	with	different	measuring	methodologyb 
(Jennings:	17.2%;	and	Nield:	8.8%	increase;	P	<	0.001).21,30 Cheyette 
(2007)	and	Jennings	et	al	(2014)	reported	improvements	in	glycae‐
mic control. The reduction in insulin usage reported by Cheyette 
is	10.1	±	16.4	units	 (P	<	0.01);	and	an	average	of	56.5	mmol/mol	 in	
HbA1cc reported by two studies.16,21	Jackson	et	al	(2007)	reported	a	
significant	improvement	in	FBS	by	a	reduction	by	0.36	mmol/L	from	
baseline.	 Jackson	 also	 reported	 improvement	 in	BP	with	 a	 signifi‐
cant	mean	reduction	of	9.0	mmHg	systolic	and	5.8	mmHg	diastolic	
(P	<	0.001)	 and	 a	 mean	 reduction	 in	 cholesterol	 by	 0.2	mmol/L	
(P	=	0.02;	Table	2).26
At	 six	 months,	 three	 studies	 (16%)	 reported	 further	 signifi‐
cant	 reduction	 in	 waist	 circumference	 with	 an	 average	 of	 6.6	cm	
(P	<	0.001).21,28,30	 The	waist	 circumference	 averaged	 at	 120.3	cm.	
The	average	reduction	in	HbA1c	from	five	studies	(26%)	is	calculated	
at	4.86	mmol/mol	(P	<	0.05).16,17,20,21,32	Rowe	et	al	(2005)	reported	
further significant reductions in insulin usage by a calculated mean 
of 40.0 units (P	<	0.001).32	In	addition,	Jackson	et	al	(2007)	indicated	
a	constant	decrease	in	FBS	by	0.3	mmol/L	from	baseline	(P	=	0.03).26 
Jackson also reported an insignificant reduction in cholesterol (by 
0.15	mmol/L;	 P	=	0.6).	 Jennings	 et	 al	 (2014)	 reported	 increase	 in	
physical	 activity	 (by	26%;	P	<	0.001)	 from	baseline;	whereas	Nield	
et	al	(2016),	reported	a	decline	(from	123.2	min/wk	at	3	months	to	
107.4	min/wk	at	6	months).21,30 The calculated average reduction in 
BP	was	 reported	by	 two	studies	 (11%);	with	an	average	 reduction	
in	systolic	BP	by	10.2	mmHg	and	diastolic	by	1.3	mmHg	from	base‐
line.21,30 Five studies reported the drop‐out rate with an average of 
33.4%,	ranging	from	18%	to	60%	(Table	2).20,22,28,30,32
At	one	 year,	HbA1c	 average	 results	 calculated	 from	 two	 stud‐
ies	 (11%)	was	 found	 to	 reclaim	 to	 the	 baseline	 calculated	 average	
(59.4	 compared	 to	58.8	 at	 baseline).16,21	Turner	 et	 al	 (2015),	 how‐
ever,	noted	 that	36%	of	participants	 reported	a	 reduction	 in	 insu‐
lin usage.15	 Cheyette’s	 (2007)	 participants	 experienced	 a	 similar	
reduced level of mean insulin usage as they did at three months 
(62.0	±	30.4	 units).16	 Similarly,	 Jackson	 et	 al’s	 (2007)	 participants	
had	 FBS	 tested	 as	 similar	 levels	 as	 three	 months	 of	 intervention	
(5.04	±	0.60	mmol/L).	Jackson	also	reported	an	insignificant	change	
in cholesterol.26	Both	Jackson	et	al	(2007)	and	Jennings	et	al	(2014)	
reported	 a	 statistically	 significant	 decrease	 in	BP	with	 an	 average	
systolic	 reduction	 of	 11.5	mmHg	 and	 in	 diastolic	 by	 6.76	mmHg	
(P	=	0.001).21,26	Only	one	study	(6%)	reported	physical	activity	with	
a similar level as the three‐month point of intervention (scored 2.8 
compared	to	2.9	at	three	months).21 Waist circumference remained 
relatively constant compared to six‐months point; with a mean re‐
ported by one study 118.8 cm.21	 Eight	 studies	 reported	 increased	
drop‐out	rate	with	an	average	of	44.1%	ranging	from	15.6%	to	78.3%	
(Table	2).18,21,23,25‐27,31,33
At	eighteen	and	twenty‐four	months,	there	were	little	or	no	sec‐
ondary outcome variables reported by any of the included studies. 
3 mo 6 mo 12 mo 18 mo 24 mo
≥5%	weight	loss 23.98(7)a 39.20(9) 43.35(7) 47.90(1) 44.40(1)
≥10%	weight	loss 3.6(1) 10.0(2) 29.4(2) 26.0(1) 20.0(2)
≥5	kg	weight	loss 27.20(2) 39.21(2) 40.90(2) 13.60(1)
≥10	kg	weight	
loss
36.0(1)
aSuperscript	 in‐brackets	numbers	represent	count	of	studies	contributed	in	calculating	the	corre‐
lated average. 
TA B L E  3   Calculated average rates of 
participants who have lost weight covered 
and	reported	by	the	included	studies	(%)
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Drop‐out	rate	increased	to	an	average	of	74.13%	at	two	years	point;	
ranging	 from	 62.0%	 to	 80.5%,	 as	 reported	 by	 4	 studies.21,29,31,32 
Table	2	summarize	drop‐out	rates	form	included	studies.
4  | DISCUSSION
Although	obesity	has	an	 increasing	acadaemic	and	clinical	 interest	
globally,	the	evidence	on	Tier	3	and	all	other	MWMPs	in	the	UK	re‐
mains scarce.4 The aim of the present review was to examine Tier 
3	and	MWMPs	for	severely	obese	adults.	Our	review	supports	the	
accumulating	 available	 evidence	 that	 Tier	 3	 intervention	 reached	
positive influence on morbidly and among severely obese patients in 
the	pre‐bariatric	stage.	Evidence	suggests	that	Tier	3	interventions	
are	effective	obesity	treatment,	especially	during	the	early	months	
of involvement.
In	 general,	 all	MWMPs	were	 found	 to	 reduce	weight	 consid‐
erably and to improve other health outcomes measured from 
baseline on most reported variables. The magnitude of the ef‐
fect,	 however,	 seems	 to	 lose	momentum	 after	 six	months	 of	 in‐
tervention. This later observation is crucial with regards to the 
appropriate	 timing	 for	 a	 bariatric	 surgical	 intervention.	 A	 small	
number	 of	 included	 studies	 discuss	 this	 phenomenon,	 perhaps	
due to the substantial proportion of participants who drop‐out at 
an accelerating rate beyond the three‐month point of interven‐
tion.	In	addition,	more	recent	studies	have	provided	novel	insights	
into the processes and mechanisms that underpin weight regain 
after weight loss. In addition to environmental and behavioural 
factors,	physiological	(or	metabolic)	adaptations	to	weight	loss	fa‐
vour weight regain due to perturbations in the levels of circulating 
appetite‐related	hormones	and	energy	homoeostasis,	 in	addition	
to alterations in nutrient metabolism and subjective appetite. To 
maintain	weight	 loss,	 individuals	must	adhere	to	behaviours	 that	
counteract physiological adaptations and other factors favouring 
weight regain.34,35 It is difficult to overcome physiology with be‐
haviour.	Nonetheless,	 this,	 and	 variations	 in	 study	 duration	may	
contribute to preventing this review from comparing the true ef‐
fect	size	between	included	studies.	Though	future	research	is	re‐
quired	to	examine	secondary	outcome	variables	such	as	glycaemic	
control	and	lipids	(in	stratifications)	extensively,	weight	loss	goals	
such	 as	 5%	weight	 loss	 (NICE	 guidelines)	 are	 reachable	 at	 early	
stages	of	interventions	(Table	3).
We	 agree	with	Brown	et	 al’s	 (2017)	 review,	which	 notes	most	
available reviewed evidence comes from observational studies in 
which	randomized	selection	and	allocation	into	Tier	3	services	would	
improve inference reliability.12	The	only	RCT	reviewed,	for	instance,	
lasted	for	a	short	intervention	duration	(four	months)	and	reported	
a	modest	mean	reduction	in	weight	(2.2	kg).16	At	three	months,	the	
mean reduction in weight from all studies that reported changes (in‐
cluding	the	RCT)	reached	4.11	kg,	thus	almost	doubling	the	reported	
RCT‐measured effect.
Improvements in secondary health outcome variables are signifi‐
cant until the effects of the drop‐out rate become apparent. This may 
be because all studies have excluded drop‐out data from their anal‐
yses	at	each	 interval.	At	the	three‐	and	six‐months	points,	however,	
we can appreciate achieved improvements in glycaemic control and 
BP.	Most	studies	that	reported	secondary	outcome	variables	related	
magnitude	to	a	statistical	significance	in	physical	activity,	for	instance,	
the	 average	 increase	 reached	 26%	 at	 three	months	 (P	<	0.001)	 but	
declined afterwards.21,30	 Despite	 the	 high	 risk	 of	 bias	 assessment,	
we have noticed no difference in magnitude between small and large 
sample	 size	 studies.	 Studies	 that	 reported	demographic	 characteris‐
tics	such	as	SES	and/or	education	levels	did	not	reveal	distinct	effects	
either.	Thus,	Tier	3	and	MWMPs	may	have	been	preventive	tools	 in	
the	 short‐	 and	mid‐term,	 treating	obesity	 regardless	 of	 sample	 size,	
demographic characteristics and/or comorbidities.
About	the	interpretation	of	data,	we	noted	that	studies	invested	
in	patients’	emotional	and	motivational	status,	and	which	reported	
data	for	depression	and	anxiety,	were	 just	as	 likely	 to	have	a	high	
rate	of	patient	drop‐outs	as	those	that	did	not.	This,	in	count,	does	
not support the notion that weight reduction levels in those pro‐
grammes were superior to other studies that did not target emo‐
tional	 health.	 McLean	 et	 al	 (2016),	 for	 instance,	 concluded	 that	
patients with complex obesity who scored high for severe anxiety 
and/or depression participating in an MWMP with integrated psy‐
chological	 support,	 achieved	 similar	 weight	 reduction	 outcomes	
compared to non‐severe cases.24	 Thus,	 more	 research	 is	 needed	
regarding	 obese	 people’s	 mental	 wellbeing,	 process	 and	 pathway	
for psychological intervention as well as robust outcomes from such 
interventions.
A	majority	of	included	studies	were	not	as	precise	in	discussing	
participants’	 reasons	for	dropping	out.	Extending	efforts	to	assess	
and overcome drop‐outs appeared to contribute to a successful in‐
tervention	(especially	a	multicomponent	one)	and	the	achievement	
of	desired	targets.	This	is	because,	as	anticipated	by	commissioning	
parties,	Tier	3’s	main	goal	is	to	help	patients,	at	a	minimum,	to	lose	
weight	and	improve	most	of	their	quality	of	life	aspects,	improve	and	
induce	remission	of	comorbidities	or	to	optimize	patients’	prepara‐
tion	for	a	Tier	4	bariatric	surgical	intervention.	The	goal	is,	optimisti‐
cally,	helping	patients	to	take	control	of	their	own	lives	and	all	other	
healthful elements; which is the drive for commissioning all tiered 
weight reduction interventions.
Brown	et	al	(2017)	recently	published	a	systematic	review	ex‐
amining a set of criteria for interventions similar to the ones this 
review has covered.12 We have only excluded two studies from 
their	selection,	as	one	was	of	non‐British	origin	and	the	other	was	
comparing groups in post‐bariatric.13,36	They	reviewed	14	studies,	
and our conclusions were based on lines of theoretical analysis 
similar to theirs. Our review adds to the evidence base on a strati‐
fied basis with summaries for weight loss achieved and calculated 
average outcome results and suggests further research regard‐
ing	 intervention’s	high	drop‐out	 rates	as	well	 as	outcomes	 from	
psychological and physical activity interventions. More RCT‐de‐
signed	studies	would	greatly	contribute	to	robust,	 real‐life	 find‐
ings,	as	all	possible	confounding	effects	would	 ideally	distribute	
evenly.
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5  | LIMITATIONS
Studies	published	on	Tier	3	and	UK	MWMPs	are	limited	in	number.	
Yet,	most	if	not	all	of	included	studies	are	of	high	risk	of	bias	in	terms	
of	allocation	sequence,	allocation	concealment,	blinding,	incomplete	
outcome data. The only RCT reviewed has shown a modest change 
in weight compared to all included studies.16 The high rate of drop‐
outs	was	present	in	most	if	not	all	included	studies	with	inadequate	
reasoning.	The	majority	 have	excluded	non‐completers’	 data	 from	
their final analysis.
6  | CONCLUSION
The	reviewed	evidence	for	the	Tier	3	service	and	MWMPs	suggests	
a	short‐	to	mid‐ranged	positive	effect	on	British	patients	with	obe‐
sity	 (BMI	 ≥30	kg/m2)	 regarding	 accumulated	 reduction	 in	 weight,	
glycaemic	control,	BP	and	subtle	 improvement	 in	physical	activity.	
The high drop‐out rate might have contributed to limiting longer 
terms’	 progress	 in	 all	 positive	 results,	 especially	 those	 related	 to	
physical	activity.	More	randomized	trial	investigations	and	drop‐out	
explorations	 would	 improve	 overall	 reliability.	 Tier	 3	 service	 and	
MWMPs	can	assist	obese	adults	living	in	the	UK	to	lose	weight	and	
may improve their overall health status.
E THIC S S TATEMENT
Since	this	is	a	systematic	review,	ethical	request	is	not	applicable.
ACKNOWLEDG EMENT
This work was supported by the Medical Research Council [grant 
numbers	MR/K00414X/1,	MR/P021220/1];	and	Arthritis	Research	
UK	[grant	number	19891].
CONFLIC T OF INTERE S T
No conflict of interest is declared for all authors.
AUTHORS CONTRIBUTION
Alkharaiji,	M	undertook	data	 (study)	collection,	analysis	and	wrote	
the	 first	draft	of	 the	manuscript.	Anyanwagu,	U	acted	as	an	 inde‐
pendent	 second	 reviewer	 for	 study	 selection,	 supported	 analysis	
and	supported	 the	 final	draft	of	 the	manuscript.	Donnelly,	R.	pro‐
vided crucial academic input on the content of the manuscript and 
interpretation	of	data	analysis.	Idris,	I.	conceived	the	study,	provided	
academic	 supervision,	 supported	 data	 analysis	 and	 interpretation,	
and wrote the final draft of the manuscript.
DATA ACCE SSIBILIT Y
Supporting	data	are	provided	as	supplementary	information.
ENDNOTE S
aReported	and	accumulated	HbA1c	average	results	 in	this	review	will	be	
converted to mmol/mol. 
bJennings	et	al	(2014)	reported	physical	activity	through	a	4‐level	scoring	
methodology with score number 4 being inactive and score number 1 
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